Page last updated: 2024-09-03

imatinib mesylate and Osteonecrosis

imatinib mesylate has been researched along with Osteonecrosis in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (66.67)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Dholam, K; Gupta, L; Gurav, SV; Janghel, Y	1
Chen, MF; Chiang, KC; Fu, CJ; Jan, YY; Yeh, CN; Yen, TC	1
Boralevi, F; Fricain, JC; Sibaud, V; Vigarios, E	1

Reviews

1 review(s) available for imatinib mesylate and Osteonecrosis

Article	Year
[Oral toxicity of targeted anticancer therapies]. Annales de dermatologie et de venereologie, 2014, Volume: 141, Issue:5 Topics: Angiogenesis Inhibitors; Benzamides; ErbB Receptors; Glossitis, Benign Migratory; Humans; Hyperpigmentation; Imatinib Mesylate; Indoles; Maxillary Diseases; Molecular Targeted Therapy; Mouth Mucosa; Osteonecrosis; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyrimidines; Pyrroles; Radiation Injuries; Radiotherapy; Stomatitis; Stomatitis, Aphthous; Sunitinib; TOR Serine-Threonine Kinases	2014

Article

Year

[Oral toxicity of targeted anticancer therapies].

Annales de dermatologie et de venereologie, 2014, Volume: 141, Issue:5

Topics: Angiogenesis Inhibitors; Benzamides; ErbB Receptors; Glossitis, Benign Migratory; Humans; Hyperpigmentation; Imatinib Mesylate; Indoles; Maxillary Diseases; Molecular Targeted Therapy; Mouth Mucosa; Osteonecrosis; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyrimidines; Pyrroles; Radiation Injuries; Radiotherapy; Stomatitis; Stomatitis, Aphthous; Sunitinib; TOR Serine-Threonine Kinases

2014

Other Studies

2 other study(ies) available for imatinib mesylate and Osteonecrosis

Article	Year
Osteonecrosis of the jaw associated with imatinib therapy in myeloproliferative neoplasm: a rare case report. Oral surgery, oral medicine, oral pathology and oral radiology, 2021, Volume: 131, Issue:5 Topics: Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Humans; Imatinib Mesylate; Neoplasms; Osteonecrosis	2021
Osteonecrosis of the tibia associated with imatinib in metastatic GI stromal tumor. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jun-01, Volume: 31, Issue:16 Topics: Antineoplastic Agents; Benzamides; Disease Progression; Drug Administration Schedule; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Incidental Findings; Liver Neoplasms; Middle Aged; Osteonecrosis; Pain; Peritoneal Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Range of Motion, Articular; Tibia	2013

Article

Year

Osteonecrosis of the jaw associated with imatinib therapy in myeloproliferative neoplasm: a rare case report.

Oral surgery, oral medicine, oral pathology and oral radiology, 2021, Volume: 131, Issue:5

Topics: Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Humans; Imatinib Mesylate; Neoplasms; Osteonecrosis

2021

Osteonecrosis of the tibia associated with imatinib in metastatic GI stromal tumor.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jun-01, Volume: 31, Issue:16

Topics: Antineoplastic Agents; Benzamides; Disease Progression; Drug Administration Schedule; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Incidental Findings; Liver Neoplasms; Middle Aged; Osteonecrosis; Pain; Peritoneal Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Range of Motion, Articular; Tibia

2013